Monaco Asset Management’s Heron Therapeutics HRTX Stock Holding History

Monaco Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$687K	Sell	858,122 -374,900	-30%	-$434K	0.13%	60
2025 Q4	$1.6M	Buy	1,233,022 +230,546	+23%	+$285K	0.28%	53
2025 Q3	$1.26M	Sell	1,002,476 -77,524	-7%	-$123K	0.08%	58
2025 Q2	$2.24M	Buy	1,080,000 +120,000	+13%	+$245K	0.39%	43
2025 Q1	$2.11M	Sell	960,000 -252,743	-21%	-$491K	0.43%	30
2024 Q4	$1.86M	Sell	1,212,743 -465,674	-28%	-$755K	0.27%	45
2024 Q3	$3.34M	Buy	1,678,417 +165,253	+11%	+$395K	0.48%	36
2024 Q2	$5.3M	Sell	1,513,164 -300,000	-17%	-$922K	0.84%	19
2024 Q1	$5.02M	Sell	1,813,164 -413,311	-19%	-$1.04M	1.5%	19
2023 Q4	$3.79M	Buy	2,226,475 +1,529,567	+219%	+$1.68M	1.11%	29
2023 Q3	$718K	Buy	696,908 +291,908	+72%	+$415K	0.21%	59
2023 Q2	$470K	Buy	+405,000	New	+$722K	0.13%	57

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Monaco Asset Management's HRTX Position: Q1 2026 in Review

Monaco Asset Management reduced its Heron Therapeutics (HRTX) stake by 30% in Q1 2026, selling an estimated $434K and leaving 858,122 shares worth $687K. The position accounts for 0.13% of the portfolio, ranked #60.

Monaco Asset Management first reported a position in HRTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $5.3M in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

Monaco Asset Management held 858,122 shares of Heron Therapeutics worth $687K as of Q1 2026.
Monaco Asset Management sold 374,900 Heron Therapeutics shares in Q1 2026, an estimated $434K.
Heron Therapeutics made up 0.13% of Monaco Asset Management's portfolio in Q1 2026, its #60 holding.
Monaco Asset Management first reported a position in Heron Therapeutics in Q2 2023 and has held it in 12 quarters since.
Monaco Asset Management's Heron Therapeutics position peaked at $5.3M in Q2 2024.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Monaco Asset Management's 13F filing for Q1 2026, filed 11 May 2026.